Pancreas Cancer News and Archives
		For educational purposes only; not to be relied upon. Please read Pancreatica Disclaimer
	March, 24, 2000	Phase II Anti-Gastrin 17 Vaccine Trial Results
	February 4, 2000	Rubitecan Receives NDA Approval in Canada
	February 1, 2000	EMD 121974 in Phase II Trials
	January 25, 2000	Marimastat Trial Results Disappointing
	January 12, 2000	Positive Trend in Ras Vaccine Study Results
	Phase II Anti-Gastrin 17 Vaccine Trial Results March, 24, 2000 The Aphton Corporation of California presented results of a Phase II clinical trial, consisting of 30 evaluable patients with advanced pancreatic cancer, to the annual meeting of the British Society of Gastroenterology in Birmingham, England (March 21-23) in which all patients received either lover-dose or higher-dose amounts of its anti-gastrin 17 vaccine (which blocks the gastrin-17 growth factor) with no additional or concurrent therapies. The median survival duration of the evaluable patients was 6.7 months. The vaccine appeared to be well-tolerated. Plans for a Phase III clinical trial are contemplated. Rubitecan Receives NDA Approval in Canada February 4, 2000 SuperGen, Inc. of San Ramon, California has indicated that theTherapeutics Programme of Canada has approved its Investigational New Drug (IND) application for use in clinical trial studies involving the treatment of pancreatic adenocarcinoma. EMD 121974 in Phase II Trials February 1, 2000 Merck KgaA of Darmstadt, Germany has announced that the initiation of Phase II clinical trials against pancreatic adenocarcinoma beginning in October, 1999 with its angiogenesis inhibitor agent, EMD 121974. Marimastat Trial Results Disappointing January 25, 2000 British Biotech has released the results of its Phase III clinical trials comparing the effects of its agent marimastat (an orally administered matrix metalloproteinase inhibitor) plus gemcitabine against gemcitabine alone. The combination failed to demonstrate any survival advantage as compared to gemcitabine. There was a possible trend noted in that patients with less extensive disease appeared to respond better to the marimastat regimen. Positive Trend in Ras Vaccine Study Results January 12, 2000 Based on research sponsored by HYDRO ASA and Merck KgaA, Dr. Gustav Gaudernack of the Norwegian Radium Hospital presented preliminary Phase I/II clinical trial results to the Joint Congress of the British Society for Immunology & British Society for Allergy and Clinical Immunology during late November 1999 which appeared to indicate that those patients (out of a total of 38 patients with inoperable pancreatic cancer) who demonstrated an immune response to vaccination with ras peptide fragments combined with granulocyte-macrophage colony-stimulating factor, appeared to acquire survival advantage. A majority of those vaccinated demonstrated an immune response, and no serious side-effects were noted.
	These abstracts have been summarized by Pancreatica staff from contemporaneous press releases obtained from newswire services unless otherwise noted in the abstract. They are for educational purposes only and not to be relied upon. Please read Pancreatica Disclaimer
	Home | In The News | Links | Newswire | Donations FAQ | Clinical Trials Database | Research Resources | About Us
	webmaster
	©2000-2008 Pancreatica.org - All Rights Reserved www.pancreatica.org